Genprex, Inc.
Index- P/E- EPS (ttm)-0.42 Insider Own1.10% Shs Outstand47.88M Perf Week14.06%
Market Cap60.71M Forward P/E- EPS next Y-0.55 Insider Trans0.00% Shs Float47.23M Perf Month-23.56%
Income-19.60M PEG- EPS next Q-0.12 Inst Own15.30% Short Float4.14% Perf Quarter-38.66%
Sales- P/S- EPS this Y17.60% Inst Trans-2.71% Short Ratio6.85 Perf Half Y-25.89%
Book/sh0.77 P/B1.90 EPS next Y-17.90% ROA- Target Price6.50 Perf Year-59.44%
Cash/sh0.83 P/C1.75 EPS next 5Y- ROE- 52W Range1.17 - 4.07 Perf YTD11.45%
Dividend- P/FCF- EPS past 5Y-10.30% ROI- 52W High-64.13% Beta-0.50
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low24.79% ATR0.14
Employees17 Current Ratio15.00 Sales Q/Q- Oper. Margin- RSI (14)38.97 Volatility10.41% 9.10%
OptionableYes Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume0.49 Prev Close1.56
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume285.33K Price1.46
Recom2.00 SMA20-7.57% SMA50-24.41% SMA200-32.98% Volume142,420 Change-6.41%
Jan-26-21Initiated National Securities Buy $7
Apr-29-19Initiated Noble Capital Markets Outperform $5
May-17-22 08:23AM  
May-09-22 08:15AM  
May-05-22 08:30AM  
Apr-18-22 08:15AM  
Mar-31-22 07:05AM  
Mar-23-22 08:00AM  
Mar-14-22 04:48AM  
Mar-02-22 08:00AM  
Feb-15-22 09:00AM  
Feb-09-22 08:15AM  
Jan-31-22 12:04PM  
Jan-27-22 11:23AM  
Jan-24-22 07:09AM  
Jan-10-22 09:17AM  
Jan-06-22 08:05AM  
Jan-05-22 08:00AM  
Jan-04-22 12:27PM  
Jan-03-22 02:24PM  
Dec-08-21 07:07AM  
Dec-02-21 05:09AM  
Nov-30-21 05:00AM  
Nov-16-21 08:30AM  
Sep-30-21 05:21AM  
Sep-28-21 09:43PM  
Sep-27-21 06:49AM  
Sep-24-21 06:37AM  
Sep-20-21 07:00AM  
Jul-20-21 08:30AM  
Jun-23-21 08:30AM  
Jun-22-21 07:08PM  
Jun-11-21 03:32AM  
May-19-21 08:30AM  
May-10-21 08:30AM  
May-06-21 09:05AM  
May-05-21 08:55AM  
May-04-21 09:32AM  
Apr-21-21 08:30AM  
Apr-20-21 08:30AM  
Apr-12-21 08:30AM  
Apr-05-21 08:30AM  
Mar-30-21 08:30AM  
Mar-24-21 08:30AM  
Mar-01-21 08:30AM  
Feb-09-21 08:30AM  
Feb-08-21 03:30PM  
Feb-04-21 08:30AM  
Feb-01-21 01:30PM  
Jan-28-21 08:35AM  
Jan-27-21 08:30AM  
Jan-21-21 08:30AM  
Jan-14-21 08:30AM  
Jan-13-21 09:00AM  
Dec-24-20 01:02PM  
Dec-23-20 12:40PM  
Dec-22-20 01:15PM  
Dec-17-20 08:47AM  
Dec-08-20 08:16AM  
Dec-03-20 08:17AM  
Nov-30-20 02:05PM  
Nov-24-20 09:30AM  
Nov-11-20 08:16AM  
Nov-10-20 08:17AM  
Oct-30-20 08:17AM  
Oct-29-20 08:16AM  
Oct-26-20 08:16AM  
Oct-07-20 08:17AM  
Oct-06-20 08:16AM  
Sep-21-20 08:17AM  
Sep-09-20 04:25PM  
Sep-02-20 05:36PM  
Aug-26-20 08:17AM  
Aug-05-20 03:34PM  
Jul-31-20 08:17AM  
Jul-30-20 08:16AM  
Jul-21-20 12:58PM  
Jun-29-20 08:16AM  
Jun-25-20 08:17AM  
Jun-24-20 08:16AM  
Jun-16-20 08:17AM  
Jun-09-20 08:17AM  
Jun-08-20 08:17AM  
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes who currently have limited treatment options. The company works with institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Its lead product candidate is REQORSA (GPX-001), which is in preclinical stage for the treatment of non-small cell lung cancer (NSCLC). It is also developing GPX-002, a preclinical stage gene therapy for diabetes. The company also offers ONCOPREX, a nanoparticle delivery system. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.